Ambiq and CardioMedive have partnered to create Medive, a modular AI-powered cardiac care platform utilizing Ambiq’s ultra-low-power Apollo510 MCU.
The Apollo510 employs SPOT expertise for power effectivity, enabling multi-week battery life and seamless connectivity with twin SDIO interfaces. Medive integrates clinical-grade monitoring instruments, together with ECG, blood strain, SpO₂, and superior diagnostic modules like spirometry and thermal imaging.
The platform makes use of edge AI for real-time anomaly detection, affected person alerts, and predictive insights, lowering reliance on cloud-based techniques.
Medive was awarded “Medical Innovation of the Yr” by the Romanian Healthcare Awards for its developments in distant cardiovascular monitoring.
“CardioMedive is reworking all phases of the affected person’s journey for each in-home and hospital care,” says Fumihide Esaka, CEO of Ambiq. “We’re proud to energy such an vital digital well being innovation that makes efficient prevention, prognosis, and illness administration extra accessible utilizing our ultra-low energy options.”
The answer goals to enhance accessibility to hospital-grade cardiac care in numerous settings, from clinics to houses. Industrial launch is deliberate for Q3 2026 in Europe and the U.Ok., with enlargement to the U.S., Canada, and Asia-Pacific in 2027.
Associated
AI semiconductor | AI/ML | Ambiq | CardioMedive | edge AI | healthcare
